148 related articles for article (PubMed ID: 12944915)
1. Mutant p53 gain of function: repression of CD95(Fas/APO-1) gene expression by tumor-associated p53 mutants.
Zalcenstein A; Stambolsky P; Weisz L; Müller M; Wallach D; Goncharov TM; Krammer PH; Rotter V; Oren M
Oncogene; 2003 Aug; 22(36):5667-76. PubMed ID: 12944915
[TBL] [Abstract][Full Text] [Related]
2. Differential activation of the Fas/CD95 pathway by Ad-p53 in human gliomas.
Cerrato JA; Khan T; Koul D; Lang FF; Conrad CA; Yung WK; Liu TJ
Int J Oncol; 2004 Feb; 24(2):409-17. PubMed ID: 14719118
[TBL] [Abstract][Full Text] [Related]
3. Repression of the MSP/MST-1 gene contributes to the antiapoptotic gain of function of mutant p53.
Zalcenstein A; Weisz L; Stambolsky P; Bar J; Rotter V; Oren M
Oncogene; 2006 Jan; 25(3):359-69. PubMed ID: 16170349
[TBL] [Abstract][Full Text] [Related]
4. Alterations of Fas (APO-1/CD 95) gene and its relationship with p53 in non small cell lung cancer.
Boldrini L; Faviana P; Pistolesi F; Gisfredi S; Di Quirico D; Lucchi M; Mussi A; Angeletti CA; Baldinotti F; Fogli A; Simi P; Basolo F; Fontanini G
Oncogene; 2001 Oct; 20(45):6632-7. PubMed ID: 11641789
[TBL] [Abstract][Full Text] [Related]
5. Role of p53 in regulating constitutive and X-radiation-inducible CD95 expression and function in carcinoma cells.
Sheard MA; Uldrijan S; Vojtesek B
Cancer Res; 2003 Nov; 63(21):7176-84. PubMed ID: 14612511
[TBL] [Abstract][Full Text] [Related]
6. Localization of a mutant p53 response element on the tissue inhibitor of metalloproteinase-3 promoter: mutant p53 activities are distinct from wild-type.
Thomas S; Reisman D
Cancer Lett; 2006 Aug; 240(1):48-59. PubMed ID: 16236433
[TBL] [Abstract][Full Text] [Related]
7. Cooperation of two mutant p53 alleles contributes to Fas resistance of prostate carcinoma cells.
Gurova KV; Rokhlin OW; Budanov AV; Burdelya LG; Chumakov PM; Cohen MB; Gudkov AV
Cancer Res; 2003 Jun; 63(11):2905-12. PubMed ID: 12782597
[TBL] [Abstract][Full Text] [Related]
8. CD95 (Fas/APO-1) and p53 signal apoptosis independently in diverse cell types.
O'Connor L; Harris AW; Strasser A
Cancer Res; 2000 Mar; 60(5):1217-20. PubMed ID: 10728678
[TBL] [Abstract][Full Text] [Related]
9. Wild-type function of the p53 tumor suppressor protein is not required for apoptosis of mouse hepatoma cells.
Unger C; Buchmann A; Bünemann CL; Kress S; Schwarz M
Cell Death Differ; 1998 Jan; 5(1):87-95. PubMed ID: 10200449
[TBL] [Abstract][Full Text] [Related]
10. Mutant p53 exerts a dominant negative effect by preventing wild-type p53 from binding to the promoter of its target genes.
Willis A; Jung EJ; Wakefield T; Chen X
Oncogene; 2004 Mar; 23(13):2330-8. PubMed ID: 14743206
[TBL] [Abstract][Full Text] [Related]
11. The BCL6 proto-oncogene suppresses p53 expression in germinal-centre B cells.
Phan RT; Dalla-Favera R
Nature; 2004 Dec; 432(7017):635-9. PubMed ID: 15577913
[TBL] [Abstract][Full Text] [Related]
12. A novel adenoviral vector expressing human Fas/CD95/APO-1 enhances p53-mediated apoptosis.
Rakkar AN; Katayose Y; Kim M; Craig C; Ohri E; Li Z; Cowan KH; Seth P
Cell Death Differ; 1999 Apr; 6(4):326-33. PubMed ID: 10381625
[TBL] [Abstract][Full Text] [Related]
13. Tumor-specific adenoviral gene therapy: transcriptional repression of gene expression by utilizing p53-signal transduction pathways.
Kühnel F; Zender L; Wirth T; Schulte B; Trautwein C; Manns M; Kubicka S
Cancer Gene Ther; 2004 Jan; 11(1):28-40. PubMed ID: 14681724
[TBL] [Abstract][Full Text] [Related]
14. Decreased Fas expression in advanced-stage bladder cancer is not related to p53 status.
Maas S; Warskulat U; Steinhoff C; Mueller W; Grimm MO; Schulz WA; Seifert HH
Urology; 2004 Feb; 63(2):392-7. PubMed ID: 14972509
[TBL] [Abstract][Full Text] [Related]
15. Transcriptional activities of mutant p53: when mutations are more than a loss.
Kim E; Deppert W
J Cell Biochem; 2004 Nov; 93(5):878-86. PubMed ID: 15449312
[TBL] [Abstract][Full Text] [Related]
16. Tumor suppressor p53 represses transcription of RECQ4 helicase.
Sengupta S; Shimamoto A; Koshiji M; Pedeux R; Rusin M; Spillare EA; Shen JC; Huang LE; Lindor NM; Furuichi Y; Harris CC
Oncogene; 2005 Mar; 24(10):1738-48. PubMed ID: 15674334
[TBL] [Abstract][Full Text] [Related]
17. CD95-mediated apoptosis is impaired at receptor level by cellular FLICE-inhibitory protein (long form) in wild-type p53 human ovarian carcinoma.
Mezzanzanica D; Balladore E; Turatti F; Luison E; Alberti P; Bagnoli M; Figini M; Mazzoni A; Raspagliesi F; Oggionni M; Pilotti S; Canevari S
Clin Cancer Res; 2004 Aug; 10(15):5202-14. PubMed ID: 15297424
[TBL] [Abstract][Full Text] [Related]
18. Negative regulation of chemokine receptor CXCR4 by tumor suppressor p53 in breast cancer cells: implications of p53 mutation or isoform expression on breast cancer cell invasion.
Mehta SA; Christopherson KW; Bhat-Nakshatri P; Goulet RJ; Broxmeyer HE; Kopelovich L; Nakshatri H
Oncogene; 2007 May; 26(23):3329-37. PubMed ID: 17130833
[TBL] [Abstract][Full Text] [Related]
19. Effect of C-terminal deletion of P53 on heat induced CD95 expression and apoptosis in a rat histiocytoma.
Sreedhar AS; Pardhasaradhi BV; Khar A; Srinivas UK
Oncogene; 2002 Jun; 21(25):4042-9. PubMed ID: 12037686
[TBL] [Abstract][Full Text] [Related]
20. Altered trafficking of Fas and subsequent resistance to Fas-mediated apoptosis occurs by a wild-type p53 independent mechanism in esophageal adenocarcinoma.
Mahidhara RS; Queiroz De Oliveira PE; Kohout J; Beer DG; Lin J; Watkins SC; Robbins PD; Hughes SJ
J Surg Res; 2005 Feb; 123(2):302-11. PubMed ID: 15680394
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
